
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Fulcrum Therapeutics Inc (FULC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FULC (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $11.07
1 Year Target Price $11.07
2 | Strong Buy |
1 | Buy |
3 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.51% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 359.71M USD | Price to earnings Ratio - | 1Y Target Price 11.07 |
Price to earnings Ratio - | 1Y Target Price 11.07 | ||
Volume (30-day avg) 7 | Beta 2.47 | 52 Weeks Range 2.31 - 9.30 | Updated Date 08/28/2025 |
52 Weeks Range 2.31 - 9.30 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.77% | Return on Equity (TTM) -30% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 152087228 | Price to Sales(TTM) 5.12 |
Enterprise Value 152087228 | Price to Sales(TTM) 5.12 | ||
Enterprise Value to Revenue 117.4 | Enterprise Value to EBITDA -3.09 | Shares Outstanding 54091600 | Shares Floating 14586338 |
Shares Outstanding 54091600 | Shares Floating 14586338 | ||
Percent Insiders 1.82 | Percent Institutions 101.55 |
Upturn AI SWOT
Fulcrum Therapeutics Inc

Company Overview
History and Background
Fulcrum Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with genetically defined rare diseases.
Core Business Areas
- Therapeutic Development: Focused on developing therapies for genetically defined rare diseases, using FulcrumSeek platform to identify drug targets.
Leadership and Structure
The leadership team consists of experienced executives in drug development and biotechnology. The organizational structure is typical of a biotechnology company, with research, development, and commercial functions.
Top Products and Market Share
Key Offerings
- Losmapimod: A selective p38 alpha/beta MAP kinase inhibitor in clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Losmapimod is designed to reduce DUX4 expression. Competitors include Acceleron Pharma (acquired by Merck, focuses on other rare diseases but has muscular disease pipeline). Current market share for the treatment of FSHD is effectively zero for all companies as there is no approved treatment. The potential TAM will dictate future market shares.
Market Dynamics
Industry Overview
The industry is characterized by high growth potential driven by unmet medical needs in rare diseases. It's highly competitive with significant investment in R&D.
Positioning
Fulcrum Therapeutics is positioned as a pioneer in developing therapies for genetically defined rare diseases, leveraging its proprietary FulcrumSeek platform.
Total Addressable Market (TAM)
The TAM for rare disease therapies is substantial, estimated to be in the tens of billions of dollars annually. Fulcrum is positioned to capture a portion of this market through successful development and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary FulcrumSeek platform
- Strong focus on genetically defined rare diseases
- Experienced management team
- Losmapimod in clinical development
Weaknesses
- Single late-stage asset, Losmapimod carries high risk
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial outcomes
- No approved products generating revenue
Opportunities
- Expanding the pipeline with new targets identified by FulcrumSeek
- Potential for strategic partnerships and collaborations
- Positive clinical trial results leading to regulatory approval
- Expanding market reach to new geographies
Threats
- Clinical trial failures
- Competition from other companies developing therapies for rare diseases
- Regulatory hurdles and changes in approval processes
- Economic downturn affecting funding for biotechnology companies
Competitors and Market Share
Key Competitors
- DMD (DyhR)
- VRTX (Vertex Pharmaceuticals)
- MRK (Merck)
Competitive Landscape
Fulcrum faces competition from established pharmaceutical companies and other biotechnology firms developing therapies for rare diseases. Success hinges on the efficacy and safety of its products.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancement of its pipeline and R&D activities.
Future Projections: Future growth depends on the success of Losmapimod and other pipeline programs. Analyst projections vary based on clinical trial results and regulatory approvals.
Recent Initiatives: Continued clinical development of Losmapimod, expanding pipeline with new targets from FulcrumSeek, and exploring strategic partnerships.
Summary
Fulcrum Therapeutics is a clinical-stage company with a promising platform and lead asset targeting rare diseases. Its future hinges on clinical trial success and regulatory approvals. Competition in the rare disease space is intense, and the company faces financial risks given its reliance on external funding. Strong pipeline development and successful commercialization are crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulcrum Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-07-18 | CEO, President & Director Mr. Alexander C. Sapir | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.fulcrumtx.com |
Full time employees 45 | Website https://www.fulcrumtx.com |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.